Related Experiment Video
Updated: Oct 4, 2025
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Consensus for HER2 alterations testing in non-small-cell lung cancer.
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Identifying Human Epidermal Growth Factor Receptor 2 (HER2) alterations is crucial for non-small-cell lung cancer (NSCLC) patients. This consensus provides guidelines for HER2 testing to improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human Epidermal Growth Factor Receptor 2 (HER2) alterations, including mutation, amplification, and overexpression, are implicated in various cancers.
- HER2 alterations are associated with poor prognosis in non-small-cell lung cancer (NSCLC).
- Targeted therapies and antibody-drug conjugates show promise for HER2-altered cancers, including NSCLC.
Purpose of the Study:
- To establish a consensus on HER2 alteration testing in NSCLC.
- To guide the clinical management of NSCLC patients with HER2 alterations.
Main Methods:
- Expert group consensus development.
- Focus on clinicopathologic characteristics, therapies, detection methods, and diagnostic criteria for HER2-altered NSCLC.
Main Results:
- Guidelines for HER2 testing in NSCLC are proposed.
- The consensus addresses key aspects of identifying and managing HER2-altered NSCLC.
Conclusions:
- Standardized HER2 testing is essential for NSCLC patients.
- This consensus aims to enhance clinical decision-making and patient benefit from targeted therapies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025